Naratriptan is a generic equivalent form of GlaxoSmithKline’s Naramig (Naratriptan Hydrochloride), indicated in the acute treatment of the headache phase of migraine attacks with or without aura.
Teva commercial director Kim said the company wants to make more medicines accessible for more people and Naratriptan is its fifth day-one launch this year to add to its portfolio of over 700 products.
"Importantly, it also means we continue to help save the NHS over £9bn on generic prescriptions," Innes added.